Novartis is expected to re-submit the once-daily oral drug to the FDA some time before 2009, and to answer concerns about the skin lesions seen in monkeys during a clinical trial. It received an approvable letter for the drug last year.
Although it's forecasted that this drug could achieve more than $1 billion in annual sales, there are about a year behind Merck's sitagliptin (Januvia) which is currently on the market in the US.
Bloomberg.com: Health Care
Technorati Tags: Galvus, vildagliptin, Januvia, sitagliptin, Novartis, Merck,